Rare Diseases: The Hidden Epidemic | Community Health

Rare diseases, affecting approximately 3.5% of the global population, or around 263 million people, are a significant public health concern. According to the National Institutes of Health (NIH), there are over 7,000 known rare diseases, with 80% of them having a genetic origin. The rarity of these conditions often leads to delayed diagnosis, with patients experiencing an average of 7 years of misdiagnosis before receiving an accurate diagnosis. This delay can significantly impact treatment outcomes, as seen in diseases like cystic fibrosis, where early intervention can improve life expectancy by up to 10 years. The development of new treatments, such as gene therapies and orphan drugs, has improved the prognosis for some rare disease patients, with the FDA approving 12 new orphan drugs in 2020 alone. However, the high cost of these treatments, with some exceeding $1 million per year, raises concerns about accessibility and affordability, sparking debates about the role of pharmaceutical companies, governments, and healthcare systems in ensuring equitable access to life-saving medications.